Lates News

Bank of America Securities released a research report stating that in the first half of the year, CanSino's revenue increased by 31% year-on-year, and net losses narrowed. The growth in sales of MCV4 Menhycia in the first half of the year was driven by a 38.4% year-on-year increase in revenue from meningococcal vaccines. Benefiting from the increase in high-profit vaccine sales and the improvement in production capacity utilization, the gross profit margin of vaccine products in the first half of the year increased to 79.3%, a year-on-year increase of 12 percentage points. The bank raised CanSino's earnings per share forecast for 2028 to 2034 by 7%-11%, taking into account its leading research and development capabilities in various technological pathways and strong overseas expansion capabilities, reiterating a "buy" rating with a target price raised from HK$43 to HK$56.